Mostly: Classical

[Sexton O Blake]

HA! Funny, I actually am in the middle of an 180degree flip on Kerry.

Initially I thought Bush didn't have a chance - and that even though the VP is never a factor, thought Edwards wasn't as strong as Cheney in their debate.

But low and behold, I give you tidings of great joy. I gather the overall impression (major news stations) is that Kerry wasn't good enough to really change people's minds to vote for him. And that Bush didn't do that bad of a job.

Though the first was on foreign policy and Iraq etc.

Town Hall version tonight.. The Blurb

Anyways, issues don't matter to most American's I am sure.. there are more important things to worry about..

On Jay Leno Wednesday night - he had "Point, what's your point". - two college kids... girl and guy.. first is the guy..

>> Personally, I don't like kerry.

>> Jay: What don't you like?

>> First off, his face is just weird. And he looks like a horse kind of. And then his daughters aren't very cute. The first daughters are hot, though.

>> Jay: Nice of you to say, though.

>> They're not as hot as the bush daughters.

>> Jay: You feel that's important?

>> Yeah.

>> Jay: What do you feel senator kerry's strengths and weaknesses are? (to the girl)

>> I heard they gets manicures or something. That he's metrosexual.

>> Jay: What does that mean?

>> It's like straight men, but they get manicures and pedicures.

>> Jay: Is that bad?

>> No, I think every man should do that.

>> Jay: You're for it?

>> Yes, that's a strength.

.
.
.

Though the industry on the whole may be affected - with these two it was bad news for their COX-2 drugs.. pain medication seems to be causing heart attacks..

Withdrawal of Competitor's Pain Medicine Is Mixed Blessing for Pfizer

NEW YORK (AP) -- Pfizer Inc. looked like the big winner at first after Merck & Co. announced last week that its pain reliever Vioxx was being pulled from the market because of increased risks for heart attack and strokes.

Prescriptions for Pfizer's competing products, Celebrex and Bextra, initially surged, according to one report, and analysts were predicting increased sales.

But now the outlook seems less clear after European regulators said they were launching a safety investigation into the entire class of drugs that includes Vioxx, Bextra and Celebrex. Then an editorial in the New England Journal of Medicine raised questions about the safety of the drugs known as COX-2 inhibitors.

Anyways, watching PFE..